Clinical Trial Update: Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment [Phase 3]

View source ↗

Summary

A Phase 3 completed trial comparing glycemic control between insulin glargine (Lantus) and a third oral agent in patients with diabetes mellitus who failed prio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED